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Background and purpose: Curative radiotherapy/chemo-radiotherapy for head and neck cancer (HNC)
may result in severe acute and late side effects, including tube feeding dependence. The purpose of this
prospective cohort study was to develop a multivariable normal tissue complication probability (NTCP)
model for tube feeding dependence 6 months (TUBEM6) after deﬁnitive radiotherapy, radiotherapy plus
cetuximab or concurrent chemoradiation based on pre-treatment and treatment characteristics.
Materials and methods: The study included 355 patients with HNC. TUBEM6 was scored prospectively in a
standard follow-up program. To design the prediction model, the penalized learning method LASSO was
used, with TUBEM6 as the endpoint.
Results: The prevalence of TUBEM6 was 10.7%. The multivariable model with the best performance con-
sisted of the variables: advanced T-stage, moderate to severe weight loss at baseline, accelerated radio-
therapy, chemoradiation, radiotherapy plus cetuximab, the mean dose to the superior and inferior
pharyngeal constrictor muscle, to the contralateral parotid gland and to the cricopharyngeal muscle.
Conclusions: We developed a multivariable NTCP model for TUBEM6 to identify patients at risk for tube
feeding dependence. The dosimetric variables can be used to optimize radiotherapy treatment planning
aiming at prevention of tube feeding dependence and to estimate the beneﬁt of new radiation
technologies.
 2014 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 113 (2014) 95–101
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nd/3.0/).Head and neck cancer (HNC) can have a profound impact on
swallowing function [1–5]. The treatment of these patients with
radiotherapy (RT), chemoradiation (CRT) or radiotherapy plus
cetuximab (CetRT) may further affect swallowing function, eventu-
ally leading to tube feeding dependence. Incidences of tube feeding
dependence at 2 years after treatment of up to 51% have been
reported [6–10]. Ronis et al. showed that at 1 year after treatment,
the presence of a feeding tube was the most powerful predictor ofquality of life in HNC patients [11], thus indicating the clinical
importance of preventing tube feeding dependence.
One strategy for preventing swallowing dysfunction is to reduce
the dose to anatomical structures that are important for swallow-
ing by using advanced radiation delivery techniques such as inten-
sity modulated radiotherapy (IMRT) [12–18]. However,
radiotherapy treatment optimization requires information on the
most important dose–volume parameters. A multivariable model
is used for this purpose. However, no multivariable normal tissue
complication probability (NTCP) models have yet been published
on tube feeding dependence after curative RT or CRT for HNC.
Therefore, the main objective of this study was to develop a multi-
variable NTCP model for tube feeding dependence.
96 Prediction model for tube feeding dependenceMaterials and methods
Patients
The population of this multicenter prospective cohort study was
composed of 355 consecutive patients treated at two different
institutions. These patients with cancer of the mucosal surfaces
of the larynx, oropharynx, oral cavity, hypopharynx, nasopharynx,
paranasal sinuses, with tumors of the salivary glands and patients
with lymph node metastases from an unknown primary tumor,
received curative primary RT, CRT or CetRT.
Baseline weight loss was deﬁned as the percentage of total body
weight lost during the 6 months prior to radiation, with 1–10%
weight loss deﬁned as moderate weight loss, and more than 10%
deﬁned as severe weight loss (assessed by either the dietician or
radiation oncologist).Treatment
Treatment details have been previously described [19,20]. In
summary, all patients were treated with either conventional 3D
conformal radiotherapy (3D-CRT) or IMRT to a total dose ranging
between 50 and 70 Gy. Patients treated with concomitant CRT were
treatedwith conventional fractionation (2.0 Gy per fraction, 5 times
per week up to 70 Gy in 7 weeks). Chemotherapy consisted of cis-
platin 100 mg/m2 on day 1, 22 and 43, or 3 cycles of carboplatin
(300–350 mg/m2) on day 1 and 5-ﬂuorouracil (5-FU) on day 1–4
as a continuous infusion (600 mg/m2/24 h) every 3 weeks. All
patients treated with CRT received a prophylactic percutaneous
endoscopic gastrostomy (PEG) feeding tube prior to commencing
treatment. Patients with stage I–II and those with stage III–IV
whowere considered not eligible for CRTwere treatedwith acceler-
ated RT with (2.0 Gy per fraction, 6 times per week up to 66–70 Gy
in 6 weeks). Since 2008, patients with locally advanced (stage III–
IV) tumors, in whom chemotherapy was considered not feasible,
have been treated with cetuximab using a loading dose of
400 mg/m2 1 week prior to RT and aweekly dose of 250 mg/m2 dur-
ing accelerated RT.
At both institutions, prophylactic PEG tube placement was the
standard of care in all patients treated with curative concomitant
chemoradiation. Furthermore, patients were instructed not to use
the PEG tube unless oral feeding became insufﬁcient due to side
effects of the treatment. In patients with signiﬁcant weight loss
(>5% weight loss in 1 month or >10% in 6 months or
BMI < 18.5 kg/m2) and/or low nutritional intake (less than half of
daily requirements for energy, proteins or ﬂuids) and/or severe
swallowing dysfunction prior to treatment, PEG tubes were placed
prior to treatment. However, these patients were excluded from
the analysis.
As we were primarily interested in radiation-induced swallow-
ing dysfunction, patients that used a feeding tube at baseline were
excluded from this analysis. Moreover, patients had to be free of
local recurrence or distant metastases at the time of assessment
of swallowing dysfunction (i.e. 6 months after treatment).
Therapeutic placement of feeding tubes was used for patients
with signiﬁcant weight loss or swallowing dysfunction during
treatment; in this situation a nasogastric feeding tube was
placed during treatment if swallowing problems were considered
to be temporary. In case of severe swallowing problems during
early treatment and/or if the problems were expected to con-
tinue for a longer period of time, there was a preference for
PEG tube placement. Referral to a speech therapist for swallow-
ing rehabilitation was only used in case of persisting severe
swallowing problems after completion of radiotherapy/chemo-
radiotherapy.Follow-up schedule and assessments
The primary endpoint was tube feeding dependence either by
PEG or nasogastric tube at 6 months after completion of treatment
(TUBEM6). Patients were considered tube feeding dependent if oral
intake was limited or not possible at all and the feeding tube was
actually used. All patients participated in a standard follow-up pro-
gram (SFP) with prospective data registration. Acute and late radi-
ation-induced side effects, as well as tube feeding dependence,
were assessed by the treating physicians.Contouring of organs at risk
The swallowing organs at risk (SWOARs) were delineated by
two radiation oncologists, according to the guidelines for SWOAR
contouring as described by Christianen et al. [21]. These organs
include the superior, middle and inferior PCM, the cricopharyngeal
muscle, the esophagus inlet muscle (EIM), the cervical esophagus,
the base of tongue and the supraglottic and glottic larynx. The par-
otid and submandibular salivary glands and spinal cord were
delineated according to the guidelines described by van de Water
et al. [22].IMRT treatment planning
The deﬁnition of the clinical target volumes was used as previ-
ously described [23,24]. At one institution the pencil beam algo-
rithm was used for dose calculation and at the other institution
the collapsed cone algorithm.
For each patient, two Planning Target Volumes (PTVs) were
deﬁned: a prophylactic PTV to which a total dose of either 46 or
54.25 Gy was prescribed (PTV46 or PTV54) for elective node levels,
and a therapeutic PTV for which the prescribed total dose was
either 60 or 70 Gy (PTV60 or PTV70) for the primary tumor and
pathological lymph nodes. Each patient received between 30 and
35 fractions. The dose values were not corrected for fraction size
effects. The different dose levels were treated with either a simul-
taneous integrated boost (SIB) or a consecutive boost technique.
For each patient, an IMRT treatment plan was created. At least
98% of each PTV had to be covered by 95% of the prescribed dose,
and the maximum doses delivered to the spinal cord, brainstem,
optic nerves and optic chiasm were not allowed to exceed 54, 60,
54 and 54 Gy, respectively. The maximum planned dose was not
allowed to exceed 77 Gy, and the volume receiving 75 Gy was
not allowed to be larger than 2 cm3. The dose to the parotid and
submandibular glands and other unspeciﬁed tissues outside of
the prophylactic PTV was reduced as much as possible [16].Statistical analysis
The variance inﬂation factor (VIF) was calculated to check for
high collinearity between variables. For each SWOAR multiple
dosimetric variables were available in the dataset. However,
because these were generally highly collinear among each other
we selected only the mean dose as candidate variables for each
SWOAR.
To develop the prediction model, ﬁrstly a univariable analysis
was performed for the set of candidate predictor variables to show
the raw uncorrected effects of each variable for TUBEM6. Secondly,
the least absolute shrinkage and selection operator (LASSO)
method was used, which is a multivariable logistic regression anal-
ysis with a constraint on the absolute magnitude of the regression
coefﬁcients [25,26]. This method included all candidate predictor
variables in the modeling process, but only a subset of variables
are eventually included in the model; the coefﬁcients of variables
Table 1
Pre-treatment characteristics.
Variable Total cohort
Number %
Sex Male 270 76
Female 85 24
Age 18–65 years 227 64
>65 years 128 36
T-classiﬁcation Tis-T1 57 16
T2 158 45
T3 78 22
T4 62 18
N-classiﬁcation N0 202 57
N1 33 9
N2 3 1
N2a 12 3
N2b 31 9
N2c 67 19
N3 7 1
Primary site Larynx 189 53
Oropharynx 100 28
Oral cavity 18 5
Hypopharynx 27 8
Nasopharynx 17 5
Other 4 1
Treatment
modality
Conventional radiotherapy 56 16
Accelerated radiotherapy 197 56
Chemoradiation 88 25
Radiotherapy + cetuximab 14 4
Radiation
technique
3D-conformal radiotherapy 181 51
Intensity modulated radiation therapy 174 49
Neck irradiation Primary alone 62 18
Primary + ipsilateral neck 22 6
Primary + ipsilateral and contralateral
neck
271 76
Baseline weight
loss
No weight loss 238 67
K. Wopken et al. / Radiotherapy and Oncology 113 (2014) 95–101 97that have negligible effects are set to zero. The LASSO method has
been successfully applied to build a normal tissue complication
probability (NTCP) model for HNC patients [27]. Given the
inclusion of categorical variables in the current data, the group
LASSO (a variant of LASSO) was used for building the prediction
models.
For this analysis, the environment for statistical computing R (R
Development Core Team, R: A language and Environment for sta-
tistical Computing, Version 2.15, Vienna, 2012) was used. The
package ‘grpreg’ was used to build the group LASSO model. The
amount of shrinkage was selected by optimizing the Bayesian
information criterion (BIC) over the regularization path. To validate
the prediction power of the model, a 10-fold cross-validation
scheme with random resampling was applied and repeated
100 times. The same scheme was used to calculate the conﬁdence
intervals of the model coefﬁcient estimates. In the cross-validation
scheme the amount of model shrinkage was allowed to vary.
Model performance was described using various validation
measures [28,29]. The discriminating ability of the model was
described by the area under the curve (AUC) value based on the
Receiver Operating Characteristics curve. The discrimination slope
was calculated as the absolute difference between the mean pre-
dicted NTCP value for patients with and without the outcome.
To evaluate whether the actual model performance was within
the expected range as predicted by the model, we performed
Monte-Carlo simulation to generate the expected distributions of
the performance measures based on the model predictions. Then
we calculated the p-value of the actual model performance mea-
sures based on the observed outcomes with respect to the
expected distribution.
Finally, a Hosmer–Lemeshow test with 10 groups was per-
formed to evaluate the calibration of the model. The statistical sig-
niﬁcance level for all tests was set to p < 0.05.Weight loss 1–10% 95 27
Weight loss >10% 22 6
Baseline
swallowing
No swallowing problems 302 85
Mild swallowing problems, soft diet 49 14
Moderate swallowing problems, liquid
diet
4 1Results
Univariable analysis
The patient population consisted of 355 patients: 76% male and
24% female with a mean age of 62 years. The patients and treat-
ment characteristics are listed in Table 1. Out of 355 patients, 38
(10.7%) were tube feeding dependent at 6 months after completion
of treatment. In the univariate analysis, younger age, higher T-clas-
siﬁcation, higher N-classiﬁcation, primary tumor site of orophar-
ynx, nasopharynx and hypopharynx, CRT, bilateral neck
irradiation, weight loss at baseline and swallowing dysfunction
at baseline were all signiﬁcantly associated with TUBEM6. In addi-
tion, signiﬁcant associations with TUBEM6 were found for the mean
doses to most SWOARs, except for the PCM inferior, the cricopha-
ryngeal muscle and the glottis (Table 2).LASSO analysis
Following the LASSO model learning procedure, the multivari-
able model with the best performance consisted of the following
variables: moderate and severe weight loss prior to treatment,
advanced T-stage, bilateral irradiation of the neck, accelerated
radiotherapy, combined treatment with radiotherapy and chemo-
therapy, combined treatment with radiotherapy and cetuximab
and accelerated radiotherapy. In addition, the mean dose to the
PCM superior, to the PCM inferior, to the contralateral parotid
gland and to the cricopharyngeal muscle, respectively, were
included in the model (Table 3).
In individual cases, the risk of tube feeding dependence at
6 months after treatment can be estimated using the following
equation:NTCP ¼ ð1þ eSÞ1where, S =11.70 + (advanced T-stage * 0.43) + (moderate weight
loss * 0.95) + (severe weight loss * 1.63) + (accelerated radiotherapy *
1.20) + (chemoradiation * 1.91) + (radiotherapy plus cetuximab *
0.56) + (mean dose PCM superior * 0.071) + (mean dose PCM inferior
* 0.034) + (mean dose contralateral parotid * 0.006) + (mean dose
cricopharyngeal muscle * 0.023)
The regression coefﬁcients of the variables included in the
model are listed in Table 4. For the dosimetric variables in the
equation the dose in Gy can be ﬁlled in, while for all the other vari-
ables 0 (=no) or 1 (=yes) can be ﬁlled in.
The variance inﬂation factor (VIF) showed collinearity (VIF > 5)
for the dosimetric variables but not for the non-dosimetric vari-
ables. The VIF was 65 for all the variables that were included in
the eventual model, indicating only minor collinearity for these
variables.
Model performance at internal validation was excellent, with an
actual AUC of 0.88 (not statistically different from the AUC
expected from Monte Carlo simulations, p = 0.66; Appendix 1).
The discrimination slope had a value of 0.27 (p = 0.78). The Hos-
mer–Lemeshow chi square had a value of 5.53 (p-value 0.70) indi-
cating good agreement between expected and observed rates
(Appendix 2). The calibration plot (Fig. 1) illustrates that the
Table 2
Results of the univariable logistic regression analysis with tube feeding dependence at 6 months (TUBEM6) as primary endpoint.
Variable Univariable analysis
Odds ratio (95% CI) p-Value
Sex Female 1.00
Male 0.75 (0.35–1.58) 0.45
Age 18–65 years 1.00
>65 years 0.30 (0.12–0.74) 0.009
T-classiﬁcation Tis-T2 1.00
T3–T4 5.98 (2.73–13.08) <0.001
N-classiﬁcation N0 1.00
N+ 7.08 (3.02–16.58) <0.001
Primary Site Larynx 1.00
Oral cavity 5.78 (0.98–34.03) 0.052
Nasopharynx 6.17 (1.04–36.46) 0.045
Oropharynx 13.82 (4.62–41.28) <0.001
Hypopharynx 16.19 (4.36–60.13) <0.001
Other * *
Treatment modality Conventional radiotherapy 1.00
Accelerated radiotherapy 1.29 (0.27–6.16) 0.747
Radiotherapy + cetuximab 4.50 (0.58–35.21) 0.152
Chemoradiation 10.71 (2.43–47.32) 0.002
Radiation technique 3D-conformal radiotherapy 1.00
Intensity modulated radiation therapy 1.69 (0.85–3.35) 0.136
Neck irradiation Local/unilateral 1.00
Bilateral 6.39 (1.50–27.10) 0.012
Baseline swallowing No swallowing problems 1.00
(grading according to RTOG) Mild swallowing problems, soft diet 3.21 (1.46–7.04) 0.004
Moderate swallowing problems, liquid diet 11.08 (1.50–82.06) 0.019
Baseline weight loss No weight loss 1.00
1–10% weight loss 4.11 (1.88–8.98) <0.001
>10% weight loss 13.04 (4.66–36.50) <0.001
PCM superior mean dose (Gy) 1.09 (1.05–1.13) <0.001
PCM middle mean dose (Gy) 1.14 (1.07–1.21) <0.001
PCM inferior mean dose (Gy) 1.02 (0.99–1.05) 0.255
Cricopharyngeus muscle mean dose (Gy) 1.01 (0.99–1.03) 0.486
EIM mean dose (Gy) 1.03 (1.01–1.05) 0.004
Supraglottis mean dose (Gy) 1.07 (1.02–1.12) 0.003
Glottis mean dose (Gy) 1.00 (0.98–1.02) 0.983
Ipsilateral parotid gland mean dose (Gy) 1.06 (1.03–1.08) <0.001
Contralateral parotid gland mean dose (Gy) 1.06 (1.04–1.08) <0.001
Ipsilateral submandibular gland mean dose (Gy) 1.13 (1.06–1.19) <0.001
Contralateral submandibular gland mean dose (Gy) 1.10 (1.05–1.14) <0.001
Cervical esophagus mean dose (Gy) 1.04 (1.02–1.06) 0.001
Base of tongue mean dose (Gy) 1.07 (1.04–1.11) <0.001
Abbreviations: RTOG, Radiation Therapy Oncology Group; PCM, pharyngeal constrictor muscle; EIM, esophageal inlet muscle. For dose variables OR: increase per 1 Gy increase
in dose.
* n = 4, no OR calculated.
Table 3
Results of the LASSO analysis with tube feeding dependence at 6 months (TUBEM6) as
primary endpoint.
Variable OR OR 95% CI p-Value
T-classiﬁcation
Tis-T2 1.00
T3–T4 1.53 (1.17–2.06) <0.001
Baseline weight loss
No weight loss 1.00
Moderate weight loss (1–10%) 2.58 (2.01–3.19) <0.001
Severe weight loss (>10%) 5.08 (3.32–7.30) <0.001
Treatment modality
Conventional fractionation 1.00
Radiotherapy + cetuximab 1.74 (1.50–2.01) <0.001
Accelerated fractionation 3.33 (2.40–4.53) <0.001
Chemoradiation 6.73 (4.00–10.98) <0.001
Dosimetric variables
PCM superior mean dose (Gy) 1.07 (1.04–1.09) <0.001
PCM inferior mean dose (Gy) 1.03 (1.01–1.05) 0.006
Contralateral parotid mean dose (Gy) 1.01 (1.00–1.02) 0.14
Cricopharyngeal muscle mean dose (Gy) 1.02 (1.01–1.03) 0.004
Abbreviations: OR, odds ratio; CI, conﬁdence interval; PCM, pharyngeal constrictor
muscle.
For dose variables OR: increase per 1 Gy increase in dose.
98 Prediction model for tube feeding dependenceobserved NTCP-values of TUBEM6 in this cohort are in close prox-
imity of the predicted NTCP-values. At double cross validation
(10-fold  100 cycles) the AUC was good with a value of 0.85 (SD
0.007).Discussion
In the current study, we developed a multivariable NTCP model
for tube feeding dependence after curative RT, CRT or CetRT in HNC
patients based on pretreatment and treatment variables, including
dosimetric parameters. The ﬁnal multivariable model consisted of
several prognostic variables that can be used to identify patients at
high risk for persistent tube feeding dependence and to optimize
radiotherapy treatment planning based on the mean doses to 4
critical structures, including the superior PCM, the inferior PCM,
the cricopharyngeal muscle and the contralateral parotid gland.
Model performance was excellent.
These results are in line with previous studies [12,13,30–32],
and also with a recent study speciﬁcally looking at tube feeding
requirement [33], since we found that the dose to the inferior and
superior pharyngeal constrictor muscle, and the cricopharyngeal
Table 4
The regression coefﬁcients and multiplication values for the variables included in the model for tube feeding dependence.
Variable Regression coefﬁcient 95% CI Multiplication value
Constant 11.7 (13.47 to 8.47) –
T-classiﬁcation
T3–T4 0.43 (0.16–0.73) 0 = no, 1 = yes
Baseline weight loss
Moderate weight loss (1–10%) 0.95 (0.70–1.16) 0 = no, 1 = yes
Severe weight loss (>10%) 1.63 (1.20–1.99) 0 = no, 1 = yes
Treatment Modality
Radiotherapy + cetuximab 0.56 (0.40–0.70) 0 = no, 1 = yes
Accelerated radiotherapy 1.20 (0.87–1.51) 0 = no, 1 = yes
Chemoradiation 1.91 (1.39–2.40) 0 = no, 1 = yes
Dosimetric variables
PCM superior mean dose (Gy) 0.071 (0.044–0.082) Dose in Gy
PCM inferior mean dose (Gy) 0.034 (0.006–0.053) Dose in Gy
Contralateral parotid mean dose (Gy) 0.006 (0–0.019) Dose in Gy
Cricopharyngeal muscle mean dose (Gy) 0.023 (0.006–0.034) Dose in Gy
Abbreviations: PCM, pharyngeal constrictor muscle; Gy, gray.
Fig. 1. Calibration plot for the predictive model for tube feeding dependence at
6 months (TUBEM6) at internal validation. The solid line represents the calibration
graph of the model and the black points represent the Hosmer–Lemeshow groups.
The dashed line represents the identity line.
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that the dose to the contralateral parotid gland was identiﬁed as a
signiﬁcant prognostic factor for TUBEM6. To our knowledge, ours is
the ﬁrst study to ﬁnd such a relationship. This is in line with nor-
mal physiology, given that the parotid glands are largely responsi-
ble for salivary output during meals [34] and with previous
research on reducing the dose to the parotid glands using IMRT
in patients with HNC [35,36]. Our results are also supported by a
study on xerostomia after CRT [37]. Another prospective study
found that both xerostomia (p = 0.038) and dysphagia
(p = 0.0032) were reduced if both salivary glands were spared
[38]. Swallowing difﬁculties are, therefore, probably caused by a
combination of damage to pharyngeal constrictors and xerostomia.
The results of the current study conﬁrm that next to reducing
the dose to the pharyngeal musculature, further reduction of the
contralateral parotid gland dose may contribute to prevention of
severe swallowing dysfunction in terms of tube feeding
dependence.
We did not ﬁnd an association between the mean dose to the
ipsilateral parotid gland and TUBEM6. Usually, the mean dose to
the ipsilateral parotid gland is higher than the mean dose to the
contralateral gland, and in many cases beyond the tolerance dose
despite the use of IMRT. Recent studies have shown that only the
mean dose to the contralateral parotid gland was associated with
xerostomia [39], which supports our ﬁndings.
A number of authors reported on radiation delivery technolo-
gies aiming at optimizing the dose to swallowing organs at risk[12–17]. Amin et al. showed that by using IMRT planning to reduce
the dose to the pharyngeal constrictor muscles and the larynx and
esophageal inlet muscle, the duration of PEG-tube dependence
could be reduced by 4.9 months [18]. Currently, a prospective
study on swallowing-sparing IMRT is ongoing at our own depart-
ment, and the results will be available soon.
The present study also showed that the risk of TUBEM6 doubled
in patients treated with accelerated RT compared to conventional
fractionation. This conﬁrms the importance of treatment modali-
ties on TUBEM6. In other studies, patients treated with CRT and Cet-
RT also had markedly increased risks of TUBEM6 [6,10].
In contrast to our results, the DAHANCA study on locoregional
tumor control in squamous-cell carcinoma [40] showed no
increase in late toxicity, including dysphagia, in patients treated
with accelerated radiotherapy. This is probably due to a number
of differences in the study designs: (1) 69% of the patients in our
study population treated with accelerated radiotherapy received
bilateral neck irradiation, while in the DAHANCA study only 28%
of patients treated with accelerated radiotherapy had a node posi-
tive neck; (2) after a maximum of 50 Gy in 5 weeks, they reduced
the ﬁelds to include only the initially macroscopically known gross
tumor volume with a margin of 1 cm. (3) the neck could be treated
with electrons to reduce the dose to the spinal cord, while in our
current study, 54 Gy was given to the neck with photons. However,
it should be noted that the primary endpoint in the current analy-
sis was set to 6 months after completion of treatment, and that
tube feeding dependence may reﬂect consequential acute effects
that may further decrease over time.
In the study by Bonner et al. [41], patients treated with CetRT
were compared with patients treated with radiotherapy only. In
that study, no increase in acute and late toxicity was seen in
patients treated with CetRT compared to the group treated with
only radiotherapy, whereas in our study patients treated with Cet-
RT had an increased risk of TUBEM6. The policy at both institutions
is to reserve CetRT for patients with stage III-IV HNC who are not
eligible for CRT, and thus represent a population with lower perfor-
mance and more co-morbidity. Therefore, the higher incidence in
this subgroup may reﬂect a higher vulnerability for side effects
rather than the additional effect of cetuximab to radiotherapy.
A possible limitation of our study is that all patients treated
with CRT received prophylactic PEG placement. Consequently, no
conclusions can be made about the effect of prophylactic PEG tube
placement on late tube feeding dependence. The usefulness of pro-
phylactic PEG tube placement is currently under debate. Some
studies have suggested that prophylactic PEG tube placement
may not always be necessary, which is supported by the results
of Madhoun et al., indicating that about half of patients used their
100 Prediction model for tube feeding dependencePEG-tube for 2 weeks or less [42]. Other studies have suggested
that prophylactic PEG tube placement resulted in worse diet out-
come [43]. One study reported more persistent dysphagia and a
greater need for pharyngoesophageal dilatation after PEG tube
placement [44]. Williams et al. [45] found that enteral feeding
was markedly prolonged with prophylactic gastrostomy as com-
pared to nasogastric feeding tubes that were placed when medi-
cally required. However, in our study patients were encouraged
to continue supplementary oral feeding for as long as possible
and were also encouraged to commence oral feeding as soon as
possible after completion of treatment.
In a future study, we are going to look into automated model-
based optimized planning of IMRT plans for head and neck cancer
patients. This is aimed at sparing the structures that are included in
this model, without compromising tumor coverage.
Conclusion
The present study is the ﬁrst to provide a multivariable NTCP
model for tube feeding dependence after curative RT, CRT or CetRT
in a population-based cohort of patients with HNC. Future studies
could use this model to identify patients at risk for tube feeding
dependence after treatment who may beneﬁt from prophylactic
measures.
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